Molecular Classification and Risk Stratification

2013 ◽  
pp. 55-64
Author(s):  
Shaji Kumar ◽  
Rafael Fonseca ◽  
Keith Stewart
Keyword(s):  
Risk Stratification ◽  
Molecular Classification

scholarly journals Ubiquitin-related Molecular Classification and Risk Stratification of Hepatocellular Carcinoma

2021 ◽  
Author(s):  
Si Yang ◽  
Bowen Yao ◽  
Liming Wu ◽  
Yuanxing Liu ◽  
Kang Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Stratification ◽  
Molecular Classification

scholarly journals MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification

2018 ◽  
Vol 32 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Narasimhan P. Agaram ◽  
Michael P. LaQuaglia ◽  
Rita Alaggio ◽  
Lei Zhang ◽  
Yumi Fujisawa ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Spindle Cell ◽  
Molecular Classification ◽  
Sclerosing Rhabdomyosarcoma ◽  
Aggressive Subtype

Abstract 4760: Molecular classification and risk-stratification in medulloblastoma using an integrative genomic approach

2011 ◽  
Author(s):  
Yoon-Jae Cho ◽  
Pablo Tamayo ◽  
Aviad Tsherniak ◽  
Matthew Meyerson ◽  
Jill P. Mesirov ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Molecular Classification ◽  
Genomic Approach

Histology and Fusion Status in Rhabdomyosarcoma

2013 ◽  
pp. 425-428 ◽  
Author(s):  
Erin R. Rudzinski
Keyword(s):  
Soft Tissue ◽  
Risk Stratification ◽  
Diagnostic Criteria ◽  
Prognostic Value ◽  
Molecular Classification ◽  
Embryonal Rhabdomyosarcoma ◽  
Intermediate Risk ◽  
Oncology Group ◽  
Continued Use

The International Classification of Rhabdomyosarcoma (ICR) has provided diagnostic criteria for rhabdomyosarcoma (RMS) and formed the basis of histologic risk stratification since its publication in 1995. However, the recognition of new variants of embryonal rhabdomyosarcoma (ERMS), shifts in the diagnostic criteria of alveolar rhabdomyosarcoma (ARMS), the increasing use of myogenin immunohistochemistry and recognition of the distinct biologic properties associated with fusion status all raised questions about the continued use of this classification system in the diagnosis and treatment of patients with RMS. Recent Children's Oncology Group Soft Tissue Sarcoma Committee analysis of histology and fusion status in the intermediate risk RMS study D9803 refined the histologic criteria of RMS. We validated the new diagnostic criteria against fusion status, allowing prospective examination of the prognostic value of histology compared with fusion status for risk-stratification of patients with RMS. This article summarizes the evolution of and current practices in the histologic and molecular classification of rhabdomyosarcoma.

scholarly journals EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN’S HAEMATOLOGY/ONCOLOGY GROUP

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii315-iii315
Author(s):  
Chia Huan Ng ◽  
Denise Obrecht ◽  
Molly Buntine ◽  
Olivia Wells ◽  
Martin A Campbell ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Surgical Resection ◽  
Molecular Analysis ◽  
Treatment Decision ◽  
Progression Free Survival ◽  
Molecular Classification ◽  
Disease Recurrence ◽  
Outcome Data ◽  
Treatment Decision Making ◽  
Supratentorial Ependymoma

Abstract AIM Advances in molecular classification of paediatric ependymoma have been pivotal in improving risk stratification and understanding of this disease. C11orf95-RELA fused supratentorial ependymoma (ST-EPN) have been reported to have a poor outcome, with 10-year overall survival (OS) of 49% and progression free survival (PFS) of 19%. A cohort of patients from multiple international institutions with molecularly confirmed C11orf95-RELA fused ST-EPN were reviewed to assess their disease behaviour. METHOD: We reviewed patients with molecularly determined C11orf95-RELA supratentorial ependymoma diagnosed between 1999 – 2019. Demographic information, extent of surgical resection, use of radiotherapy and/or chemotherapy, disease recurrence, treatment at recurrence and clinical outcome data was collected. PFS and OS of all patients were estimated using Kaplan-Meier method. RESULTS A total of 76 ST-EPN patients with C11orf95-RELA fusion were identified (median age: 7 years3 months, range: 5 months – 18 years7 months). 58 patients (76.3%) had complete surgical resection. 70 patients(92.1%) received radiotherapy. 55 patients(72.3%) received chemotherapy. The 10-year OS of C11orf95-RELA fused ST-EPN was 72.4% and PFS was 63.8%. In contrast, ST-EPN at a single institution with unconfirmed molecular status had an OS of 61.1% and PFS of 34.9%. CONCLUSION Detailed molecular analysis identified distinct subgroups of patients with ST-EPN. Patients from this cohort with C11orf95-RELA methylation profiles had a significantly higher OS compared to previous reports and those with unconfirmed fusion status, emphasising the critical importance of complete molecular profiling to assist in treatment decision making. Complete molecular analysis in future prospective cohorts is essential for accurate risk stratification and treatment selection.

scholarly journals Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5848
Author(s):  
Jenneke C. Kasius ◽  
Johanna M. A. Pijnenborg ◽  
Kristina Lindemann ◽  
David Forsse ◽  
Judith van Zwol ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Risk Stratification ◽  
Adjuvant Treatment ◽  
Molecular Classification ◽  
Figo Stage ◽  
Developed Countries ◽  
Surgical Staging ◽  
Molecular Profile ◽  
Prognostic Information ◽  
Main Challenge

Endometrial cancer (EC) is the most common gynaecologic malignancy in developed countries. The main challenge in EC management is to correctly estimate the risk of metastases at diagnosis and the risk to develop recurrences in the future. Risk stratification determines the need for surgical staging and adjuvant treatment. Detection of occult, microscopic metastases upstages patients, provides important prognostic information and guides adjuvant treatment. The molecular classification subdivides EC into four prognostic subgroups: POLE ultramutated; mismatch repair deficient (MMRd); nonspecific molecular profile (NSMP); and TP53 mutated (p53abn). How surgical staging should be adjusted based on preoperative molecular profiling is currently unknown. Moreover, little is known whether and how other known prognostic biomarkers affect prognosis prediction independent of or in addition to these molecular subgroups. This review summarizes the factors incorporated in surgical staging (i.e., peritoneal washing, lymph node dissection, omentectomy and peritoneal biopsies), and its impact on prognosis and adjuvant treatment decisions in an era of molecular classification of EC. Moreover, the relation between FIGO stage and molecular classification is evaluated including the current gaps in knowledge and future perspectives.

From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management

2015 ◽  
pp. 139-145 ◽  
Author(s):  
Naveen Pemmaraju ◽  
Alison R. Moliterno
Keyword(s):  
Risk Stratification ◽  
Myeloproliferative Neoplasms ◽  
Molecular Classification ◽  
Clinical Aspects ◽  
Jak2 Mutation ◽  
History Of ◽  
The Individual ◽  
Positive Effect ◽  
Genetic Discovery ◽  
Biologic Basis

The 2005 discovery of the JAK2 mutation redefined the diagnosis and natural history of myeloproliferative neoplasms (MPNs). Most importantly, this improvement in the pathobiologic conceptualization has focused our evolution of this field from being defined as what it is not (e.g., Philadelphia [Ph]-negative) to what it is (e.g., JAK2-positive, CALR-positive) in the majority of MPN cases. In the ensuing 10 years, the field has experienced a paradigm shift in terms of understanding of the biologic basis of the development of MPNs, an explosion of knowledge of the genetics of MPNs, and has translated disease knowledge into effective targeted therapies. With greater uniformity and agreement on the diagnosis and differences among the individual MPNs, augmented by improved cytogenetic and molecular classification, attention has turned now to addressing the need for uniformity in risk stratification of patients in the clinic for both disease complications and disease transformation. This article will highlight the developments in the field with regard to risk stratification and prognostication in MPNs with focus on the clinical aspects of the patient who presents with either essential thrombocytosis (ET), polycythemia vera (PV), or myelofibrosis (MF).

scholarly journals V. Molecular classification and risk stratification of myeloma

2013 ◽  
Vol 31 (S1) ◽  
pp. 38-41 ◽  
Author(s):  
P. Leif Bergsagel ◽  
Marta Chesi
Keyword(s):  
Risk Stratification ◽  
Molecular Classification

Investigative Tools for Diagnosis and Management

Hematology ◽  
2008 ◽  
Vol 2008 (1) ◽  
pp. 298-305 ◽  
Author(s):  
Nikhil C. Munshi
Keyword(s):  
Risk Stratification ◽  
Plasma Cells ◽  
Disease Process ◽  
Disease Status ◽  
Molecular Classification ◽  
Diagnostic Tools ◽  
Recent Advances ◽  
Number Of Patients ◽  
Genomics And Proteomics ◽  
Staging Systems

Abstract Recent advances in genomics and proteomics have advanced our understanding of myeloma pathogenesis, recognized novel mediators of disease process, and identified new therapeutic targets. These developments have provided newer diagnostic tools for myeloma, improved monitoring of the disease status and allowed for molecular classification of the disease. The recent advances in investigative techniques that have helped refine the diagnostic work up in myeloma includes use of serum free light chains, especially in oligosecretory myeloma, patients with renal disease and with amyloidosis; use of MRI and PET scan in diagnosis and managing bone disease; and use of cytogenetics and fluorescent in situ hybridization (FISH) technique to determine prognosis. Newer risk stratification protocols have included international staging systems as well as FISH-detected chromosomal changes, specifically t(4;14), t(14;16), and del 17p. These improved predictive risk stratification models are guiding treatment algorithms. As the novel therapies are able to attain complete responses in a significant number of patients, the response categories are also being redefined. Immunophenotypic identification of clonal plasma cells, inclusion of free light chain response and molecular markers of disease now allow us to define stringent complete responses. Recent studies show the increasing importance of attaining complete remission to extended overall survival. The ongoing oncogenomic studies including high-throughput expression profiling, high-density single nucleotide polymorphism (SNP)–arrays and array based comparative hybridization (aCGH) have been utilized to not only understand myeloma pathobiology, but for gene discovery, identification of biomarkers, and delineation of patient subgroups to incorporate them into therapeutic strategies and to eventually provide optimal individualized therapy.

Sign in / Sign up

Export Citation Format

Share Document